Gilead, AbbVie still have plenty of hep C patients to treat; Docs, pharmacists mix up Brintellix and Brilinta;

> Next-gen hep C drugmakers Gilead ($GILD) and AbbVie ($ABBV) still have a huge treatable population, with more than 2 million untreated patients remaining in the U.S. Report

> With three products nearing biosimilar competition, Amgen ($AMGN) will be the first to defend its products in the U.S. More

> Shire ($SHPG) has picked up Foresight Biotherapeutics Inc. for $300 million in cash, gaining access to a late-stage experimental pink eye drug. Report

> China is expanding medical insurance to cover all critical illnesses for all urban and rural residents by the end of the year. More

And Finally... Lundbeck and Takeda's antidepressant Brintellix and AstraZeneca's ($AZN) anti-clotting agent Brilinta have been confused at least 50 times by doctors and pharmacists, the FDA says. More

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.